Stock Market Reviews

Read and share opinions on DWTX (Dogwood Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mark

Latest News

• Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025
  Nov 11, 2025
• DWTX: Interim Readout for Halneuron® Phase 2b Trial in CINP in 4Q25…
  Nov 10, 2025
• Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
  Nov 6, 2025
• Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025
  Oct 30, 2025
• Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025
  Oct 14, 2025
• DWTX: Licenses SP16 for Treatment of Cancer Related Pain…
  Oct 10, 2025
• Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit
  Oct 7, 2025
• Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
  Sep 3, 2025
• DWTX: Over 50 Patients Enrolled Thus Far in Phase 2b Halneuron® Trial; Interim Read Out in 4Q25
  Aug 20, 2025
• Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial
  Aug 7, 2025
• Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025
  Aug 6, 2025
• Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference
  Jun 3, 2025
• DWTX: Phase 2b Trial in Chemotherapy Induced Neuropathic Pain Underway…
  May 13, 2025
• Dogwood Therapeutics Announces First Quarter 2025 Financial Results
  May 8, 2025
• Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
  May 1, 2025
• Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance
  Apr 11, 2025